The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response

The therapeutic landscape of drugs targeting the DNA damage response (DDR) is rapidly expanding; however, an urgent unmet need remains for validated predictive biomarkers of response. SLFN11 has emerged as a promising predictor of sensitivity to DNA-damaging chemotherapies, and recently, been associated with sensitivity to PARP inhibition. We discuss its use as a predictive biomarker of response for targeting the DDR.

Automated summary

SLFN11 has emerged as a promising predictor of sensitivity to DNA-damaging chemotherapies and PARP inhibition, making it a potential biomarker for targeting the DDR.